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EDITORIAL
Renal failure: A state of nitric oxide deficiency?
In this issue, Schmidt and Baylis confirm what has in excellent agreement with a recent analysis of arginine-
been expected by many—though not all—nephrologists, to-citrulline conversion rates in uremic subjects, using
that is, that whole body nitric oxide (NO) production is 15N2-arginine as a substrate for NOS and measuring isoto-
reduced in renal failure. This observation eliminates any pic plasma enrichment of 15N-citrulline by mass spec-
doubt about the direction in which NO production is trometry (LCMS) [12]. This information obtained with
changed, that is, the composite result of the activities of different methodology is in excellent agreement with
the NO synthase (NOS) isoforms. As all good scientific and complements the observation of Schmidt and Baylis
communications, however, this observation also raises [1]. This point is important, since a priori reduced NOx
(and leaves unanswered) a number of issues. excretion in the urine might not be the result of reduced
The results of this study should be viewed against the synthesis, but of increased elimination of NOx via alter-
background of past controversies. Using platelets [2] and native pathways, for example, interaction with oxygen
mononuclear cells stimulated by contact with bioincom- radicals. In the steady state, reduced renal clearance of
patible membranes [3], some investigators postulated that NOx should not affect NOx excretion rates, but given
NO production was stimulated in renal failure. In con- the rather high plasma NOx in the study of Schmidt
trast, Vallance and Moncada reported that the plasma and Baylis one wonders whether NOx clearance is not
concentrations of asymmetric dimethylarginine (ADMA) reduced. There are also observations of diminished ace-
were elevated in uremic subjects [4]. The NO inhibitory tylcholine-mediated vasodilation in patients with chronic
properties of this compound were documented by in renal failure [13,14], presumably reflecting diminished
vitro (rat aortic ring contraction, inhibition of macrophage generation of NO upon stimulation, although the indirect
NOS activity) and in vivo studies (blood pressure in- evidence on increased baseline NO production, if con-
crease in guinea pigs, forearm vasoconstriction in healthy firmed, would potentially point to further complexities.
volunteers). The statistical power of the study of Schmidt and
Since the beginning the issue of ADMA concentra- Baylis is restricted because of the limited sample size and
tions has been plagued by methodological difficulties. unfortunately the study is incomplete because ADMA,
Nevertheless, two recent studies provided evidence for SDMA, and cGMP were not measured in all subjects
increased ADMA plasma concentrations in patients with [1]. The issue of sample size is not trivial, since renal
renal failure [5,6]. However, we do not know whether patients may be heterogenous. At least in experimental
such ADMA concentrations are inhibitory in vivo [7] studies, renal NOS activity was shown to be very much
and whether the increased concentration is exclusively model-dependent (for example, inflammatory vs. nonin-
the result of diminished renal excretion. The latter is flammatory) [8,9,15]. Unfortunately, the failure to mea-
somewhat unlikely in view of the observation that the sure the above parameters in all patients also precludes
isomer SDMA does not rise strictly in parallel with strong conclusions about factors correlated to NOx ex-
ADMA. Indeed, altered enzymatic breakdown of ADMA cretion and thus provides limited mechanistic insight.
has not been thoroughly excluded [5]. What are the implications of the findings of Schmidt
Against this background, what is the main message of and Baylis [1]? The authors propose the reasonable hy-
the study of Schmidt and Baylis [1]? Both in experimen- pothesis that diminished availability of NOx is important
tal [8,9] and clinical [10,11] studies it had previously in the genesis of hypertension of renal disease. Even
been found that urinary excretion of NOx, that is, the more important may be the role of deficient NOx avail-
excretion of nitrate and nitrite, an index of the generation ability on function and integrity of endothelial cells with
of NO, is low in renal failure. However, these studies implications for atherogenesis, vascular complications,
were not definite, since they did not control for a crucial vasomotor tone, etc. It is also not clear whether a similar
confounder: dietary intake of NOx. In this respect, the malfunction of NOS is present in specific compartments,
results of the present study are clear cut. They are also such as the central or peripheral nervous system, with
implications for the neuropsychiatric complications of
uremia. Finally, there are certain limitations concerningKey words: excretion of NOx, l-arginine, uremia, end-stage renal dis-
ease, hypertension, blood pressure. the generalizability of these results. Diminished NOx gen-
eration under unstressed conditions does not exclude thatÓ 2000 by the International Society of Nephrology
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